Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Evaluating the role of fruiquintinib in patients with refractory mCRC

Cathy Eng • 31 May 2024
ASCO 2024
Colorectal Cancer Gastrointestinal Cancer Fruiquintinib Regorafenib Tipiracil Trifluridine
FRESCO FRESCO-2

Cathy Eng, MD, Vanderbilt-Ingram Cancer Center, Nashville, TN, discusses the impact of the approval of fruiquintinib, a VEGF inhibitor, in patients with refractory metastatic colorectal cancer (mCRC). Findings from the FRESCO (NCT02314819) and FRESCO-2 (NCT04322539) trials, which assessed fruiquintinib in patients from China and the rest of the world respectively. In the FRESCO-2 trial, patients who have progressed on trifluridine–tipiracil or regorafenib were recruited, and the primary endpoint of overall survival was met. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Cathy Eng

1:07
Integrating fruquintinib into clinical practice in heavily pretreated CRC
Cathy Eng • 31 May 2024
0:50
Exploring the potential of fruquintinib in earlier treatment settings
Cathy Eng • 31 May 2024
0:45
Identifying and managing adverse events of fruiquintinib for CRC
Cathy Eng • 31 May 2024

Related Videos

1:36
CheckMate 9DW: the future of checkpoint inhibitors in advanced HCC
Laura Williams Goff • 6 Jun 2024
2:32
Choosing efficacious treatment options for hepatocellular carcinoma
Laura Williams Goff • 6 Jun 2024
2:20
ORCHESTRA: tumor debulking in metastatic colorectal cancer
Elske Gootjes • 2 Jun 2024
1:15
ABC-07 : chemotherapy with or without SBRT in cholangiocarcinoma
Laura Williams Goff • 6 Jun 2024
The content of VJOncology is intended for healthcare professionals